Naltrexone: Research History & Formulation Comparisons

How the research connects to the formula

Low-dose research needs to retain its dose and the condition under study. A publication about a different naltrexone regimen can contribute to the ingredient history without answering the question posed by this product.

The atlas connects the low-dose product to the broad literature and to a more focused search sample. It does not combine results from unrelated diagnoses into a single response estimate.

Current HealthRX.com formulation map
Product	Listed formulation	Connected ingredient research
Low Dose Naltrexone (LDN)	Low Dose Naltrexone 1.5 to 4.5 mg	Naltrexone

Publication history

When the ingredient appeared in the literature

The chart counts records mentioning the search terms in their title or abstract. It includes research beyond longevity. Use the period controls to inspect the count.

2026: 274 indexed publications. 2026 includes publications dated through October 5. The earlier bars cover longer periods than the annual bars.

View the chart as a data table

Period	Publications
1900-1959	0
1960-1969	0
1970-1979	209
1980-1989	1008
1990-1999	1426
2000-2009	1782
2010-2014	1050
2015-2019	1206
2020	304
2021	299
2022	274
2023	243
2024	296
2025	351
2026	274

Search query and data source

Source: Europe PMC’s PubMed-indexed records. Retrieved October 5, 2026. The index’s firstPublicationDate field supplies the dates and chart periods; it can normalize a month-only record to the first day of the month. Dates through October 5 are included. Counts can change as the index adds or corrects records.

TITLE_ABS:(naltrexone) AND SRC:MED AND FIRST_PDATE:[1900-01-01 TO 2026-10-05]

Open this literature search · Download the data

A closer search for this product question

The focused search returns 86 publications. It narrows the ingredient query to terms connected with its catalog use. Its displayed records remain a search sample, not a ranking of study quality.

View the focused query

TITLE_ABS:(naltrexone) AND TITLE_ABS:(("low dose" AND randomized)) AND SRC:MED AND FIRST_PDATE:[1900-01-01 TO 2026-10-05]

Open the focused search

Dated publications

Read individual records in context

The timeline combines selected references with a sample from the ingredient search. Dates use the index’s firstPublicationDate field; the PubMed record may distinguish an earlier online date from the print date. Written study notes appear alongside the records that have them. Other entries show the indexed bibliography and link to the paper.

Published Erratum · correction · Corrected and Republished Article · Journal Article

Corrigendum: Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.

Hariyanto TI, Vatvani AD, Patel P, Yanto TA. The Korean journal of pain. PMID 41469220.

This record identifies a publication and its indexed publication types. The full paper contains the study methods, population, formulation and results.

Read the PubMed record · Publisher record

Questions that shape the comparison

Does the publication actually use a low-dose regimen? What diagnosis, control group and follow-up period define its result?

Source records

Corrigendum: Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.Hariyanto TI, Vatvani AD, Patel P, Yanto TA.The Korean journal of pain. 2026-01-01. PMID 41469220. Published Erratum, correction, Corrected and Republished Article, Journal Article.

Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial.Nielsen MJ, Vaegter HB, Bruun KD.Pain management nursing : official journal of the American Society of Pain Management Nurses. 2026-08-12. PMID 42586891. Journal Article.

Adjunctive oral naltrexone for breakthrough craving in patients receiving extended-release injectable naltrexone for alcohol use disorder: Three cases.Felipe Tosta G, Duarte Freitas RP, Alamir M, Basra A, Salzman B, Harp J, Barnett BS, Anand A.Journal of addictive diseases. 2026-08-13. PMID 42592908. Journal Article.

Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol-Associated Cirrhosis: NAL-CI Trial.Alla M, Varshney M, Bhardwaj A, Kumar G, Shasthry SM, Sarin SK.Liver international : official journal of the International Association for the Study of the Liver. 2026-09-01. PMID 42615276. research-article, Randomized Controlled Trial, Journal Article.

Low-Dose Naltrexone in Crohn's Disease: A Prematurely Terminated Randomized Trial Showing Reduced Fatigue Without Clinical or Endoscopic Benefit.van de Pol N, Paulides E, Wolfhagen FHJ, West RL, Holster IL, Verweij KE, de Vries AC, Fuhler GM, van der Woude CJ.Digestive diseases and sciences. 2026-09-06. PMID 42701992. Journal Article.

A scoping review of naltrexone treatment for opioid use disorder: Clinical hurdles and successes.Comer SD, Mondello JE, Castillo F.Preventive medicine. 2026-09-16. PMID 42749222. Journal Article.

From Naltrexone Induction to Response-Guided Care in Alcohol-Associated Cirrhosis.Mao X, Hu X.Liver international : official journal of the International Association for the Study of the Liver. 2026-10-01. PMID 42703711. Letter.

Correction: Low-Dose Naltrexone: What is the Evidence? A Narrative Review.Gouda AHK, Aitcheson NEC, Steadman KJ.Advances in therapy. 2026-10-01. PMID 42412315. Published Erratum, correction.

Research data assembled by HealthRX.com from the displayed source records, October 5, 2026. The atlas contains a dated literature search and selected studies; it is not an exhaustive systematic review.